The role of nitric oxide and prostaglandin E-2 on the hyperalgesia induced by excitatory amino acids in rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, YH | - |
dc.contributor.author | Shin, CY | - |
dc.contributor.author | Lee, TS | - |
dc.contributor.author | Huh, IH | - |
dc.contributor.author | Sohn, UD | - |
dc.date.available | 2019-05-30T10:34:00Z | - |
dc.date.issued | 2000-04 | - |
dc.identifier.issn | 0022-3573 | - |
dc.identifier.issn | 2042-7158 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/25331 | - |
dc.description.abstract | The present study was designed to investigate the role of nitric oxide (NO), N-methyl-D-aspartate (NMDA) receptor and prostaglandins on hyperalgesia induced in rats by excitatory amino acids and the possibility that prostaglandins may act as the retrograde messenger in the spinal cord like NO. N omega-nitro-L-arginine methyl ester (L-NAME; 500 mu g/paw, intraplantarly (i.pl.)), MK-801 (10 mu g/paw, i.pl.) or indomethacin (300 mu g/paw, i.pl.) reduced the duration of phase 2 of the biting/licking and scratching (B/L + S) response induced by formalin injection from 255.6+/-16.7s to 155.6+/-16.9, 172.2+/-33.3 or 205.6+/-16.7s, respectively. L-NAME (0.3 mg, i.th.), MK-801 (8 mu g, i.th.) or indomethacin (20 ug, i.th) reduced the duration of phase 2 of the B/L+S response induced by saline injection from 288.5+/-7.7s to 207.7+/-19.2, 184.6+/-7.7 or 192.3+/-38.5 s, respectively. L-NAME or indomethacin injected into the spinal cord of the rat significantly reduced the hyperalgesia induced by NMDA (1 mu g, i.th.) from 43.8+/-4.6% to 12.3+/-3.1 and 19.2+/-2.3%, respectively. It is assumed that NO produced by excitatory amino acids may increase prostaglandin production by cyclooxygenase activation. L-NAME, MK-801 or indomethacin injected into the rat spinal cord significantly reduced the hyperalgesia induced by prostaglandin E-2 (PGE(2), 25 ng, i.th.) in the tail-flick test from 40.6+/-3.5% to 18.2+/-3.2, 18.8+/-1.8 or 17.6+/-4.1%, respectively, but had little effect on hyperalgesia in the paw pressure test (except for indomethacin). In conclusion, NO and PGE2 affect the hyperalgesia induced by excitatory amino acids. It is suggested that PGE2, like NO, may act as a retrograde messenger in the spinal cord. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | The role of nitric oxide and prostaglandin E-2 on the hyperalgesia induced by excitatory amino acids in rats | - |
dc.type | Article | - |
dc.identifier.doi | 10.1211/0022357001774039 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PHARMACY AND PHARMACOLOGY, v.52, no.4, pp 431 - 436 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000086625200011 | - |
dc.identifier.scopusid | 2-s2.0-0033994508 | - |
dc.citation.endPage | 436 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 431 | - |
dc.citation.title | JOURNAL OF PHARMACY AND PHARMACOLOGY | - |
dc.citation.volume | 52 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | FORMALIN TEST | - |
dc.subject.keywordPlus | SUBSTANCE-P | - |
dc.subject.keywordPlus | SPINAL-CORD | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | INVOLVEMENT | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | MESSENGER | - |
dc.subject.keywordPlus | MORPHINE | - |
dc.subject.keywordPlus | BEHAVIOR | - |
dc.subject.keywordPlus | AGENTS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.